Plasma Serotonin in Autism

Pediatric Neurology

Volumn 35, Issue 3, 2006, Pages 182-186

  Connors, Susan L ^a   Matteson, Karla J ^c   Sega, Gary A ^c   Lozzio, Carmen B ^c   Carroll, Roger C ^c   Zimmerman, Andrew W ^a,b,c  

^a KENNEDY KRIEGER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; AUTISM; BRAIN DEVELOPMENT; CHILD; CHILD DEVELOPMENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FAMILY; FATHER; FEMALE; HUMAN; MALE; MOTHER; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SEROTONIN BLOOD LEVEL; SIBLING;

ADOLESCENT; ADULT; AUTISTIC DISORDER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FATHERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTHERS; PILOT PROJECTS; SEROTONIN; SIBLINGS; TRYPTOPHAN;

EID: 33747887678     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2006.02.010     Document Type: Article

References (29)

1. Hampton T. Fetal environment may have profound long-term consequences for health. JAMA 292 (2004) 1285-1286
2. Van den Bergh B.R.H., and Marcoen A. High antenatal maternal anxiety is related to ADHD symptoms, externalizing problems, and anxiety in 8- and 9-year-olds. Child Dev 75 (2004) 1085-1097
3. 14-serotonin in pregnant rats. Am J Obstet Gynecol 95 (1966) 290-295
4. Shemer A., Whitaker-Azmitia P.M., and Azmitia E.C. Effects of prenatal 5-methoxytryptamine and parachlorophenylalanine on serotonergic uptake and behavior in the neonatal rat. Pharmacol Biochem Behavior 30 (1988) 847-851
5. Butkevich I.P., Khozhai L.I., Mikhailenko V.A., and Otellin V.A. Decreased serotonin level during pregnancy alters morphological and functional characteristics of tonic nociceptive system in juvenile offspring of the rat. Reprod Biol Endocrinol 1 (2003) 96
6. Whitaker-Azmitia P.M., Lauder J.M., Shemmer A., and Azmitia E.C. Postnatal changes in serotonin receptors following prenatal alterations in serotonin levels. Further evidence for functional fetal serotonin receptors. Brain Res 430 (1987) 285-289
7. Anderson G.M., Freedman D.X., Cohen D.J., et al. Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry 28 (1987) 885-900
8. Hanley H.G., Stahl S.M., and Freedman D.X. Hyperserotonemia and amine metabolites in autistic and retarded children. Arch Gen Psychiatry 34 (1977) 521-531
9. Abramson R.K., Wright H.H., Carpenter R., et al. Elevated blood serotonin in autistic probands and their first degree relatives. J Autism Dev Disord 19 (1989) 397-407
10. Stahl S.M. The human platelet. A diagnostic and research tool for the study of biogenic amines in psychiatry and neurologic disorders. Arch Gen Psychiatry 34 (1977) 509-516
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (1994), American Psychiatric Association, Arlington, VA
12. Schopler E., Reichler R.J., and Renner B.R. Childhood Autism Rating Scale (1999), Western Psychological Services, Los Angeles, CA
13. Racke K., Reimann H., and Kilbinger H. Regulation of 5-HT release from enterochromaffin cells. Behav Brain Res 73 (1996) 83-87
14. Gobbi G., Mirandola P., Tazzari P.L., et al. Flow cytometry detection of serotonin content and release in resting and activated platelets. Br J Haematol 121 (2003) 892-896
15. Sanders-Bush E., and Mayer S.E. 5-Hydroxytryptamine (serotonin) receptor agonists and antagonists. In: Hardman J.G., and Limbird L.E. (Eds). Goodman and Gilman's The pharmacological basis of therapeutics (1996), McGraw-Hill, New York 250
16. Sarrias M.J., Artigas F., Martinez E., et al. Decreased plasma serotonin in melancholic patients. A study with clomipramine. Biol Psychiatry 22 (1987) 1429-1438
17. Castrogiovanni P., Blardi P., De Lalla A., Dell'Erba A., and Auteri A. Can serotonin and fluoxetine levels in plasma and platelets predict clinical responses in depression?. Psychopharmacol Bull 37 (2003) 102-108
18. Nordeng H., Lindemann R., Perminov K.V., and Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 90 (2001) 288-291
19. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354 (2006) 579-587
20. Chugani D.C., Muzik O., Behen M., et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 45 (1999) 287-295
21. Sarrias M.J., Cabre P., Martinez E., and Artigas F. Relationship between serotoninergic measures in blood and cerebrospinal fluid simultaneously obtained in humans. J Neurochem 54 (1990) 783-786
22. Narayan M., Srinath S., Anderson G.M., and Meundi D.B. Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol Psychiatry 33 (1993) 630-635
23. Buznikov G.A., Lambert H.W., and Lauder J.M. Serotonin and serotonin-like substances as regulators of early embryogenesis and morphogenesis. Cell Tissue Res 305 (2001) 177-186
24. Mulder E.J., Anderson G.M., Kema I.P., et al. Platelet serotonin levels in pervasive developmental disorders and mental retardation. Diagnostic group differences, with-in group distribution, and behavioral correlates. J Am Acad Child Adolesc Psychiatry 43 (2004) 491-499
25. Ferguson H.B., Pappas B.A., Trites R.L., Peters D.A., and Taub H. Plasma free and total tryptophan, blood serotonin, and the hyperactivity syndrome. No evidence for the serotonin deficiency hypothesis. Biol Psychiatry 16 (1981) 231-238
26. Pastuszak A., Schick-Boschetto B., Zuber C., et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 269 (1993) 2246-2248
27. Nulman I., Rovet J., Stewart D.E., et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336 (1997) 258-262
28. FDA public health advisory. Paroxetine (December 2005), Center for Drug Evaluation and Research, Food and Drug Administration, Washington, DC. http://www.fda.gov/cder/drug/advisory/paroxetine200512.htm (www.fda.gov/cder/drug/advisory/paroxetine200512.htm)
29. Gallagher S., Lekagul K., and Roberts S. Response to the SSRI citalopram for children with autism spectrum disorder. [abstract]. International Meeting for Autism Research May 7, 2005, Boston, Massachusetts (2005)